|
Hydrocortisone Clinical Trials
6 actively recruiting trials across 4 locations
▼ -1 trial since May 2026
Also known as: Cortisone, Hydrocortisone Sodium Phosphate, Hydrocortisone Sodium Succinate
Pipeline
Early 1: 1Phase 1: 2Phase 3: 2Phase 4: 1
Top Sponsors
- Merck Sharp & Dohme LLC2
- Therapeutic Advances in Childhood Leukemia Consortium1
- Copenhagen Respiratory Research1
- C17 Council1
- Andrew E. Place, MD1
Indications
- Cancer5
- Acute Leukemia of Ambiguous Lineage in Relapse1
- Lymphoblastic Lymphoma, Refractory1
- Lymphoblastic Lymphoma, in Relapse1
- Treatment-Related Acute Myeloid Leukemia1
Other2 trials
Tucson, Arizona1 trial
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
The University of Arizona Cancer Center - North Campus ( Site 0073)
Phase 3
Los Angeles, California1 trial
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Children's Hospital Los Angeles
Phase 1
Orange, California1 trial
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)
Phase 3
San Francisco, California1 trial
Venetoclax Basket Trial for High Risk Hematologic Malignancies
University of California San Francisco-Benioff Children's Hospital
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.